Mandate

Vinge’s Forensic, Risk & Compliance Group assists Tele2

Tele2 has decided to leave Kazakhstan and has today published the terms and conditions governing the transaction.

In connection with the exit, Tele2 has issued the extensive report "Tele2 Kazakhstan - Exit Report on Ethics and Compliance". The Exit Report is part of Tele2’s obligation to act ethically, to fight corruption and be transparent to shareholders and the market. 
 
Vinge’s Forensic, Risk & Compliance Group has assisted Tele2 in conjunction with the company’s analysis and reporting of the anti‑corruption work which Tele2 has conducted since it arrived in Kazakhstan. In the Exit Report, Tele2 describes its method of identifying and addressing corruption risks. This method is based on Vinge’s formulated best practice – a compliance programme consisting of 10 steps which companies and organizations should implement in order to prevent bribery and corruption in their business operations. 

“It is very satisfying to work with a company which takes the risks of corruption seriously. It is not possible to prevent everything, although you can establish a framework and procedures which minimize the risk significantly”,

says Mia Falk, Head of Forensic, Risk & Compliance at Vinge.

For more information, please see Tele2’s press release as well as Tele2 Kazakhstan - Exit Report on Ethics and Compliance

Vinge’s team consisted of Mia Falk and Hayaat Ibrahim.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025